A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years

HPB

Volumn 15, Issue 4, 2013, Pages 286-293

  Pelletier, Shawn J ^a   Nadig, Satish N ^a   Lee, David D ^a   Ammori, John B ^a   Englesbe, Michael J ^a   Sung, Randall S ^a   Magee, John C ^a   Fontana, Robert J ^b   Punch, Jeffrey D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SURVIVAL RATE;

EID: 84874681475     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00576.x     Document Type: Article

References (34)

1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR,. (1963) Homotransplantation of the liver in humans. Surg Gynecol Obstet 117: 659-676.
2. Lerut JP,. (2003) Avoiding steroids in solid organ transplantation. Transpl Int 16: 213-224.
3. Lake JR,. (2003) The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 9 (Suppl.): 63-66.
4. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. (1995) Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology (Baltimore, MD) 21: 30-34.
5. Charlton M, Seaberg E,. (1999) Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 5 (4 Suppl. 1): 107-114.
6. Reggiani P, Arru M, Regazzi M, Gatti S, Molinaro MD, Caccamo L, et al. (2005) A 'steroid-free' tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. Transplant Proc 37: 1697-1699.
7. Padbury RT, Toogood GJ, McMaster P,. (1998) Withdrawal of immunosuppression in liver allograft recipients. Liver Transpl Surg 4: 242-248.
8. Punch JD, Shieck VL, Campbell DA, Bromberg JS, Turcotte JG, Merion RM,. (1995) Corticosteroid withdrawal after liver transplantation. Surgery 118: 783-786; discussion 786-788.
9. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. (1997) Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 64: 1755-1760.
10. Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et al. (1991) A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 23: 2977-2983.
11. Tchervenkov JI, Tector AJ, Cantarovich M, Tahta SA, Asfar A, Naimi J, et al. (1996) Maintenance immunosuppression using cyclosporine monotherapy in adult orthotopic liver transplant recipients. Transplant Proc 28: 2247-2249.
12. Gomez R, Moreno E, Colina F, Loinaz C, Gonzalez-Pinto I, Lumbreras C, et al. (1998) Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients. J Hepatol 28: 150-156.
13. Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, et al. (1999) Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 5 (4 Suppl. 1): 48-57.
14. Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, et al. (2001) Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 7: 343-351.
15. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, et al. (2003) Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 9: 587-595.
16. Belli LS, de Carlis L, Rondinara G, Alberti AB, Bellati G, De Gasperi A, et al. (1998) Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology (Baltimore, MD) 27: 1524-1529.
17. Pageaux GP, Calmus Y, Boillot O, Ducerf C, Vanlemmens C, Boudjema K, et al. (2004) Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 10: 1454-1460.
18. Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, et al. (2005) Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 11: 61-67.
19. Figueras J, Prieto M, Bernardos A, Rimola A, Suarez F, de Urbina JO, et al. (2006) Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 19: 641-648.
20. Langrehr JM, Neumann UP, Lang M, Muller AR, Jonas S, Settmacher U, et al. (2002) First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 34: 1565-1566.
21. Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, et al. (2005) A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 18: 1336-1345.
22. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE, Jr,. (2003) Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 75: 1396-1399.
23. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. (2004) Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 78: 1488-1495.
24. Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, et al. (2005) Steroid-free induction and pre-emptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 37: 1217-1219.
25. Pirenne J, Aerts R, Koshiba T, Van Gelder F, Roskams T, Schetz M, et al. (2003) Steroid-free immunosuppression during and after liver transplantation-a 3-year follow-up report. Clin Transplant 17: 177-182.
26. Tisone G, Angelico M, Orlando G, Palmieri GP, Strati F, Di Paolo D, et al. (1999) Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids. Transplant Proc 31: 2908-2909.
27. Tisone G, Angelico M, Palmieri G, Pisani F, Anselmo A, Baiocchi L, et al. (1999) A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 67: 1308-1313.
28. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL,. (2000) Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 6: 44-53.
29. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. (2008) Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 14: 512-525.
30. Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, Gockel I, et al. (2009) Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 22: 892-905.
31. Knight SR, Morris PJ,. (2011) Steroid sparing protocols following non-renal transplants; the evidence is not there. A systematic review and meta-analysis. Transpl Int 24: 1198-1207.
32. Llado L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, et al. (2006) Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicentre randomized study. J Hepatol 44: 710-716.
33. Foroncewicz B, Mucha K, Ryszkowska E, Ciszek M, Ziolkowski J, Porowski D, et al. (2009) Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single centre. Transplant Proc 41: 3103-3106.
34. Neumann U, Samuel D, Trunecka P, Gugenheim J, Gerunda GE, Friman S,. (2012) A randomized multicentre study comparing a tacrolimus-based protocol with and without steroids in HCV-positive liver allograft recipients. J Transplant 2012: 894215.